Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Besifloxacin

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

4Total
Phase 2 (1)
Phase 3 (3)

Trial Status

Completed3
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05816070Phase 2CompletedPrimary

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis

NCT00347932Phase 3CompletedPrimary

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

NCT00348348Phase 3CompletedPrimary

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

NCT01227915Phase 3UnknownPrimary

Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis

Showing all 4 trials

Research Network

Common Treatments

  • Besifloxacin2
  • Ofloxacin1
  • Vehicle1
  • Tobradex1
  • Moxifloxacin1

Active Sponsors

  • Bausch & Lomb Incorporated2
  • IVIEW Therapeutics Inc.1
  • Azidus Brasil1

Top Investigators

Activity Timeline